Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 44

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 44
---
| ● | Risks relating to inadequate insurance coverage |

| ● | Risks relating to failure in safeguarding our computer network system |

| ● | Risks relating to outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease |

<div align='center'>19</div>

Risks Related to Our Corporate Structure

| ● | Risks relating to our Class B shareholders have higher voting rights |

Risks Related to Our Securities

| ● | Risks relating to certain existing shareholders have substantial influence over our Company and their interests may not be aligned with the interests of our other shareholders |

| ● | Risks relating to conduct substantially all of our operations outside the United States |

| ● | Risks relating to adopt certain home country practices or take advantage of certain reduced reporting requirements |

Risks Related to DiamiR

| ● | Risks related to not completing the DiamiR merger. |

| ● | Risks relating to researchers, clinicians and healthcare administrators not adopting DiamiR’s screening and diagnostic products |

| ● | Risks related to the long process associated with new product development and the inability to commercialize CogniMIR® or any other products including risks associated with obtaining reimbursement. |

| ● | Risks related to DiamiR having a sole supplier for some of the materials used in its tests and services. |

| ● | Risks related to DiamiR’s inability to enter into and maintain new clinical collaborations. |

| ● | Risks related to DiamiR’s clinical tests not performing as expected and being unable to achieve widespread market adoption among physicians. |

| ● | Risks associated maintaining and renewing licenses (CLIA and CAP) for DiamiR laboratory. |

| ● | Risks related to future changes in FDA oversight of LDTs. |

<div align='center'>20</div>

Implications of Being a Foreign Private Issuer

The Company is considered
a “foreign private issuer.” In its capacity as a foreign private issuer, the Company is exempted from certain rules under
the U.S. Securities Exchange Act of 1934, as amended (“Exchange Act”), that impose certain disclosure obligations and procedural
requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, the Company’s officers, directors and principal
shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act
and the rules under the Exchange Act with respect to their purchases